Compare Brookfield Infrastructure Partners LP (BIP) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Smith & Nephew plc — how do they compare? Brookfield Infrastructure Partners LP trades at $38.19 (market cap $17.38B), while Smith & Nephew plc trades at $30.06 (market cap $12.40B). The key difference: Brookfield Infrastructure Partners LP is the larger of the two by market cap, and Brookfield Infrastructure Partners LP pays the higher dividend (4.77%). Which is the better fit depends on your goals.
| BIP | SNN | |
|---|---|---|
Market Cap | $17.38B | $12.40B |
Sector | Industrials | Health |
52-Week High | $40.08 | $38.70 |
52-Week Low | $29.81 | $28.73 |
Enterprise Value | $79.06B | $15.17B |
Dividend Yield | 4.77% | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $37.61, down slightly by 0.11% today. The stock shows bullish technical signals with strong analyst support (81% buy ratings) and a $45.50 consensus price target. Recent earnings have been mixed with one beat and two misses, but the company maintains robust cash flows with $5.97B from operations in 2025. BIP offers a 5% dividend yield with recent H1-26 payment of $0.46 per share.
BIP presents a compelling value opportunity with discounted valuation metrics (P/S 0.73, EV/EBITDA 7.55) and strong infrastructure assets. However, investors face risks from recent earnings volatility, high P/E ratio of 57.8, and declining profit margins. The company's global infrastructure portfolio provides inflation protection and stable cash flows, supporting the bullish analyst consensus despite near-term headwinds.
SNN trades at $31.08, up 1.24% with a bullish technical signal. The company shows improving fundamentals with 2024 revenue of $5.81B and net income of $412M, while recent earnings beat expectations. Strong cash flow generation and new product launches in robotics and wound care support growth. Analyst consensus is mixed with 27% buy ratings but majority holds.
Outlook remains positive with projected revenue growth and margin expansion, though recent earnings misses and elevated valuation metrics pose risks. The stock's technical strength and fundamental recovery present opportunity, but investor caution is warranted given mixed analyst sentiment and competitive pressures in medical technology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
